A Further Investigation into the Leaked EMA Emails & Confidential Pfizer-BioNTech COVID-19 Vaccine Related Docs
In June, Trial Site News published a bombshell investigative report on the leaked European Medicine Agency (EMA) emails and other Pfizer-related confidential reports, which exposed concerning facts in the run-up to the authorization of the Pfizer-BioNTech COVID-19 vaccine. It revealed:
A politically driven race between key regulators in their rush to authorize the vaccine.
By late November 2020, regulators including, US FDA, European Medicines Agency, Health Canada and the UK’s MHRA, were all aware of the significant loss of RNA integrity of the commercial batches (~55% mRNA integrity) of the Pfizer-BioNTech vaccine compared to the clinical ones (~78% mRNA integrity). This was classified by EMA as a “major objection” along with observed visible particles, which were classified as “impurities.”
A leaked 26 November PowerPoint presentation of a meeting between Pfizer-BioNTech and the EMA revealed how this major objection was shockingly ‘resolved’- the RNA integrity specification was simply lowered to 50%, therefore half of all mRNA molecules in the commercial batches were allowed to be truncated (not intact).
The potential implications of the RNA integrity loss in terms of safety and efficacy were unknown.
True Horrors of Covid Vaccine Harm Data NOW Exposed!
My bombshell interview with data expert and ethical computer hacker, Wouter Aukema from the Netherlands, exposes the true horrors of the trove of data buried within the European Medicines Agency’s EudraVigilance case safety reporting system
My second interview with Wouter Aukema, senior data patterns & forensics analyst, who has over 30 years of experience working with governments and corporations- is the most explosive yet.
99% of Those Who Died From Virus Had Other Illness, Italy Says
More than 99% of Italy’s coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country’s national health authority.